Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Moderna est attendu en nette hausse en pré-marché après que le PDG Stéphane Bancel et l’administrateur Paul Sagan ont acheté ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

In a couple of regulatory filings with the SEC, it was revealed that Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock worth $6 million. On Monday, Bancel acquired ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

Wall Street rebondit grâce à l'exemption de droits de douane sur les véhicules La Bourse de New York a terminé en hausse ...

Moderna shares experienced a significant surge in trading on Thursday, posting a 5.58% gain in European markets and an impressive jump of up to 16% on the NASDAQ. This remarkable performance was ...

Moderna's CEO Buys MRNA Stock Last night, two purchases of Moderna's stock by a firm controlled by MRNA CEO Stephane Bancel ...

(AOF) - Moderna est attendu en nette hausse en pré-marché après que le PDG Stéphane Bancel et l’administrateur Paul Sagan ont acheté pour 6 millions de dollars d’actions de la société.